Cell and gene therapy

Focus is usually key in bringing new products and services to market in highly innovative sectors. However, to mitigate risk in a highly uncertain market, established pharma and biotech companies developing biotherapeutics should look at diversifying their portfolio through the development and/or acquisition of multiple CGT platforms across different therapeutic areas.”

We believe scaling manufacturing, improving market access, patient centricity and leveraging innovative technologies for the pre-clinical and clinical settings are the four key areas to improving accessibility to CGTs.”

Understanding the nature of the new biotherapeutics developed and how they are delivered is vital for CGT manufacturers, healthcare professionals, and patients to enable a facilitated clinical application while reducing the overall costs of these transformative therapies.”

To support the successful delivery of an increasing number of therapies to patients, it is critical to leverage digital tools and experiences across development phases and among the various stakeholders.”

To accelerate development and production of CAR-T, pharma companies may need to put in place patent cross-licensing deals, as is the case in the electronics and telecom industries. This will require companies to develop strategic patent portfolios to ensure they have the right size, geographical spread and quality to achieve success at the negotiation table.”